Skip to Content
 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Cancer Research

    New role identified for p73 gene

    Friday, April 1st, 2016

    The p53 gene is a tumor suppressor whose absence or silence contributes to cancer formation. Vanderbilt-Ingram Cancer Center investigators recently defined the role of a family member – p73. Using a p73-deficient mouse model developed in the laboratory of Jennifer Pietenpol, Ph.D., investigators led by Clayton Marshall found that p73 regulates at least 100 genes […]

    T.J. Martell Foundation lauds Pietenpol’s research

    Thursday, March 17th, 2016

    Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of Vanderbilt-Ingram Cancer Center (VICC), was honored with the Medical Research Advancement Award during the 8th Annual T.J. Martell Foundation Nashville Honors Gala held recently at the Omni Nashville Hotel. The Medical Research Advancement Award is in recognition of Pietenpol’s career as a cancer researcher. […]

    Study suggests cancer’s ‘clock’ can be rewound

    Thursday, March 17th, 2016

    Researchers at Vanderbilt University Medical Center have “turned back the clock” in a mouse model of metaplasia — precancerous stomach lesions — raising hopes that gastric cancer, a worldwide scourge that’s rising in the United States, can be prevented. “This was totally unexpected,” said James Goldenring, M.D., Ph.D., the Paul W. Sanger Professor of Experimental […]

    ROCKs and cancer invasion

    Thursday, March 17th, 2016

    Cancers become fatal mostly because of their ability to spread. Cancerous cells migrate from primary tumors and invade neighboring tissues through protrusions called invadopodia. The rigidity of the cancerous mass, the tumor-associated extracellular matrix (ECM), drives malignant behavior through the Rho/ROCK signaling pathway. In particular, the ROCK protein is mutated and overexpressed in many cancers, […]

    A clue to cell cleavage

    Thursday, March 10th, 2016

    The final step of cell division is termed cytokinesis, a process that separates one cell into two. Cytokinesis is linked to events underlying cancer and the development of diverse cell types in the human body. The cytoskeleton, networks of filamentous proteins, is key for cytokinesis. Microtubules form a barrel-shaped array called the spindle midzone, which […]

    IOM study calls for better evidence for biomarker tests

    Thursday, March 10th, 2016

    Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine. The study authors said the tests are not being uniformly adopted into […]

    Melanoma response to immune therapy

    Friday, March 4th, 2016

    Anti-PD-1 therapy – a treatment that stimulates the immune system to attack tumors – produces responses in up to 40 percent of melanoma patients. Predictive markers of response are needed to optimize patient selection, improve treatment decision-making and minimize costs. Justin Balko, Pharm.D., Ph.D., Douglas Johnson, M.D., and colleagues hypothesized that tumor expression of MHC-I […]

    Grant spurs research into how cancer cells spread

    Friday, March 4th, 2016

    Aron Parekh, Ph.D., assistant professor of Otolaryngology, has received a four-year, $790,000 Research Scholar Grant from the American Cancer Society to further his research into the mechanical and biological properties of cancer cells and the methods by which they leave the initial tumor and spread or metastasize to other parts of the body. “I am […]

    VICC treats first patient in Tennessee with novel cellular immunotherapy

    Monday, February 29th, 2016

    For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

    Chemo better option following pancreatic cancer surgery: study

    Thursday, February 25th, 2016

    A multicenter study led by Vanderbilt University Medical Center (VUMC) investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy. The study led by Alexander Parikh, M.D., MPH, associate professor of Surgery and […]

    Next Page »« Previous Page

    E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us